Our business model distinguishes us from many other companies in the “biotech sector”.  The typical biotech is a spin-off by originating scientists from a research institution that raises funds to set up their own labs and researchers to pursue a promising, but early stage idea or invention.

BioDiem’s business model is to look for more advanced “products in the making” arising from many years of research where there is already proof-of-concept, preferably in humans.  At that stage we seek to acquire the Intellectual Property or licence-in projects with viable commercial potential and put them on a development path that adds significant value prior to out-licensing them to international pharmaceutical companies to get the products to a world-wide market.

We have a strong alliance with two leading institutes in St Petersburg that have provided the strong starting points for our projects so far.  This relationship has provided us with cost-effective access to valuable research programs with advanced clinical data.  The ability to access projects at a late stage, which reduces the technical risk, is a significant advantage of our business model.

For each project we have either taken an exclusive licence outside Russia or purchased the intellectual property outright to the compounds. In every case we have taken the compounds outside Russia and had them manufactured in the West to appropriate standards.  We have had contracts written under Victorian law and wherever possible, have secured and are persuing international patents.

To effectively manage development costs we out-source our research and development requirements to appropriate institutional centres of excellence and contract research organisations.